AbbVie, Biogen, inflammatory diseases, litigation, patent, Samsung Bioepis
0 Comment
But deal with Samsung prevents US launch until mid-2023
Biocon, biosimilar, breast cancer, cancer, Mylan, Roche, Samsung Bioepis
0 Comment
Mylan and Biocon resolve biosimilar manufacturing issues
Amgen, biosimilars, inflammatory diseases, Rheumatoid arthritis, Samsung Bioepis
0 Comment
No-one can launch biosimilars until patent expires next year
endocrinology, R&D, Samsung Bioepis, Takeda
0 Comment
South Korean firm looking to develop novel drugs
AbbVie, cancer, EUSA Pharma, Gilead, hepatitis C, Merck KGaA, multiple sclerosis, Samsung Bioepis
0 Comment
biosimilar, J&J, Merck & Co, Pfizer, pricing, regulation, reimbursement, Samsung Bioepis
0 Comment
FDA approves Samsung Bioepis biosimilar.
AbbVie, Amgen, litigation, patent, psoriasis, Rheumatoid arthritis, Samsung Bioepis
0 Comment
Decision paves way for cheaper competitor in autumn 2018.
AbbVie, inflammatory diseases, litigation, patent, Rheumatoid arthritis, Samsung Bioepis
0 Comment
Samsung to take on patent thicket surrounding Humira.
biosimilars, ema, herceptin, Roche, Samsung Bioepis
0 Comment
South Korean firm trying to copy breast cancer blockbuster.
